Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Neovacs SA ( (FR:ALNEV) ).
Néovacs has disclosed the number of shares and voting rights as part of its compliance with financial regulations. The company has been issuing new shares monthly, which are primarily derived from conversions of financial instruments like OCEANE and ORA. This practice may lead to significant dilution and potential losses for shareholders due to downward pressure on share prices. Investors are advised to exercise caution given the dilutive nature of these financing operations.
More about Neovacs SA
Néovacs is a French biotechnology company engaged in research and development as well as investment activities. The company focuses on creating vaccine candidates using its kinoid® technology platform to address lupus and allergies by regulating cytokine overproduction. Additionally, Néovacs invests in promising Biotech and Medtech companies.
YTD Price Performance: -97.52%
Average Trading Volume: 11,500
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €16.12K
See more data about ALNEV stock on TipRanks’ Stock Analysis page.